【投资界，北京】华美浩联，一家致力于提供一站式的AI数字化医疗健康服务的先锋企业，于近日宣布完成近亿元的C轮融资。此次融资的参与方包括了阿米巴资本、Ventech China银钛资本及蜂巧资本等知名投资机构。这笔金额巨大的资金注入，不仅为华美浩联的未来发展提供了强大的资金支持，也为医疗健康行业的数字化转型注入了新的活力。
华美浩联成立于2017年，自成立以来，一直致力于通过AI技术和大数据分析，提升医疗健康服务的效率与质量。通过构建数字化医疗健康服务平台，华美浩联旨在为用户提供更加个性化、便捷的医疗服务，同时，也为医疗机构提供了高效的数据分析工具和解决方案，推动了医疗行业的智能化进程。
对于此次C轮融资，华美浩联表示，所获资金将主要用于服务与产品的研发、市场推广以及平台的升级与建设。这不仅意味着华美浩联将进一步深化其在AI医疗健康领域的技术积累和市场拓展，同时也将为更多用户和医疗机构提供更加优质、高效的服务，助力医疗健康行业的数字化转型。
随着数字化医疗健康服务平台的不断升级与完善，华美浩联有望在医疗健康服务领域展现出更大的潜力和影响力，为推动整个医疗行业的智能化发展贡献出重要力量。此次融资的成功，不仅体现了市场对华美浩联发展前景的看好，也为整个医疗健康行业的数字化转型提供了新的范例和动力。
华美浩联的此次C轮融资，不仅是一次资本层面的成功对接，更是医疗健康服务领域的一次重要里程碑，预示着AI技术在医疗健康领域的广泛应用和深度融合，将为用户提供更加精准、高效、便捷的医疗服务，推动医疗健康行业的创新与发展。
英语如下：
Headline: “Huameihaolian Secures Over $100 Million in Series C Funding, Accelerating AI-Driven Medical Health Service Upgrades”
Keywords: Huameihaolian, Series C Funding, AI Medical
Content: 【Investment Circle, Beijing】 Huameihaolian, a pioneering company dedicated to providing one-stop AI-powered digital medical health services, recently announced the completion of over $100 million in Series C funding. The funding was participated by notable investment firms such as Amabai Capital, Ventech China, and Bee Capital. This substantial financial injection not only provides a strong capital backing for Huameihaolian’s future development but also infuses new vitality into the digital transformation of the medical health industry.
Established in 2017, Huameihaolian has been committed to enhancing the efficiency and quality of medical health services through AI technology and big data analysis since its inception. By building a digital medical health service platform, Huameihaolian aims to provide more personalized and convenient medical services to users while also providing efficient data analysis tools and solutions to healthcare institutions, driving the advancement of the medical industry towards automation.
Regarding this Series C funding, Huameihaolian stated that the funds will be primarily used for the development of services and products, market promotion, and platform upgrading and construction. This signifies that Huameihaolian will further deepen its technical accumulation and market expansion in the AI medical health field, and provide more high-quality and efficient services to both users and healthcare institutions. This will aid in the digital transformation of the medical health industry.
With the continuous upgrading and improvement of the digital medical health service platform, Huameihaolian is expected to unlock its full potential and impact in the medical health service sector, contributing significantly to the development of the entire medical industry’s automation. The success of this Series C funding not only reflects the market’s positive outlook on Huameihaolian’s prospects but also provides a new model and impetus for the digital transformation of the medical health industry.
Huameihaolian’s Series C funding is not only a successful capital对接, but also a significant milestone in the medical health service sector, signaling the widespread and deep integration of AI technology in the medical health field, which will provide more precise, efficient, and convenient medical services to users and propel the innovation and development of the medical health industry.
【来源】https://news.pedaily.cn/202407/536971.shtml
Views: 2